AIM ImmunoTech Inc. (AMEX:AIM) is a biotechnology company focused on developing immune-based therapies for the treatment of various diseases. The company is known for its flagship product, Ampligen, which is being explored for multiple therapeutic applications. In the competitive landscape, AIM competes with other biotech firms like Aytu BioPharma, Inc. (AYTU), iBio, Inc. (IBIO), Co-Diagnostics, Inc. (CODX), Cocrystal Pharma, Inc. (COCP), and NanoViricides, Inc. (NNVC).
AIM ImmunoTech Inc. demonstrates remarkable capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 5.83%. This results in a ROIC to WACC ratio of 76.10, indicating that AIM is generating returns far exceeding its cost of capital. This metric is crucial as it shows how well the company is using its capital to generate profits.
In comparison, AIM's peers show less favorable metrics. Aytu BioPharma, Inc. has a ROIC of -2.78% against a WACC of 18.15%, resulting in a ROIC to WACC ratio of -0.15. This negative ratio suggests that Aytu is not generating enough returns to cover its cost of capital, highlighting inefficiencies in capital utilization.
Similarly, iBio, Inc. reports a ROIC of -117.47% and a WACC of 6.80%, leading to a ROIC to WACC ratio of -17.28. Co-Diagnostics, Inc. and Cocrystal Pharma, Inc. also show negative ROIC to WACC ratios of -13.01 and -13.80, respectively, indicating that these companies are struggling to generate returns that meet or exceed their cost of capital.
NanoViricides, Inc. follows the same trend with a ROIC of -111.71% and a WACC of 9.11%, resulting in a ROIC to WACC ratio of -12.27. These figures underscore the challenges faced by AIM's peers in achieving capital efficiency. AIM's strong performance in this metric highlights its effective use of invested capital to generate substantial returns, setting it apart from its peers in the biotechnology and pharmaceutical sector.
